Big Caring Group Berhad, Malaysia’s largest pharmacy chain, lists on Bursa Malaysia’s Main Market on Thursday, 19 November 2026. The IPO was priced at RM1.08 a share, the top of the range, valuing the company at about RM7.97 billion. It is Malaysia’s second-largest IPO of 2026 by funds raised, behind Sunway Healthcare Holdings’ RM2.86 billion listing in March. The public tranche was 4.31 times oversubscribed.
The group runs 668 outlets under BIG Pharmacy, CARiNG Pharmacy, Georgetown, Wellings, Ting and iCare. Husband-and-wife pharmacists Lee Meng Chuan and Lim Sin Yin opened the first BIG Pharmacy in Damansara Uptown in 2006. Private equity firm Creador backed them from 2018. In December 2023 they bought CARiNG, then the second-largest chain, for RM888.3 million, mostly with a bank loan.
According to Frost & Sullivan, Big Caring had 24.2% of Malaysian retail pharmacy revenue in 2025. Its nearest rival, Alpro, had 5.4%.

The Malaysian retail pharmacy industry is very fragmented. The 7 companies account for 44.5% of revenue, while the remaining 55.5% is fragmented.
BCG’s dominance is inherent. But does it justify the valuation, a whopping 41.5x trailing earnings?
The deal
| Shares | At RM1.08 | Goes to | |
|---|---|---|---|
| New shares | 590.5m | RM637.8m | The company |
| Creador (via Iris Pallida, IPSB) | 863.7m | RM932.8m | Creador |
| Founders’ vehicle (Uptown Paradise, UPSB) | 374.7m | RM404.6m | Lee and Lim |
| 11 other existing shareholders | 53.5m | RM57.8m | Mostly early pharmacist shareholders |
| Total | 1,882.4m | RM2,033m | 69% to sellers |
| Over-allotment option (Creador) | up to 225.1m | up to RM243.2m | Creador |
The offer is 25.5% of the enlarged 7.38 billion shares. If the over-allotment option is exercised, Creador’s total proceeds rise to about RM1.18 billion.
Post listing, below would be the shareholding percentages.
| Before IPO | After IPO | After, with over-allotment | |
|---|---|---|---|
| Lee Meng Chuan and Lim Sin Yin (direct and via UPSB) | 54.9% | 45.4% | 45.4% |
| Creador | 33.7% | 19.3% | 16.3% |
The founders are not cashing in on the IPO on the shares held in their own names. They are, however, selling the shares held under UPSB (their investment vehicle).
Cornerstone investors have committed to 665.5 million shares (9.0% of the company, about RM719 million at RM1.08). There are 19 of them, including the IFC, JPMorgan Asset Management, FIL (Fidelity), abrdn, First Sentier, Eastspring, Principal, AHAM, Kenanga and Mawer. Retail investors get 267.6 million shares (3.6%): 147.6 million for the public and 120 million for directors, staff and other eligible persons. The rest goes to institutions, including 922.7 million shares for MITI-approved Bumiputera investors.
Creador, the founders, UPSB and the other selling shareholders cannot sell for six months after listing. After that, Creador’s remaining 16% to 19% stake is a likely source of new supply.
IPO proceeds and usage

Let me reassure you that the IPO usage is not a mistake. RM431.3 million goes to a lump sum due on 28 December 2026 on the RM831.3 million syndicated term loan from Maybank and RHB, which funded the CARiNG and Medispec acquisitions. The remaining RM139.4 million clears or reduces three revolving credit lines. Clearing the borrowings saves about RM26.3 million in interest a year.
In plain terms, the IPO is partly a refinancing. Without it, Big Caring would need to repay or refinance RM431 million about six weeks after listing. The IPO funds will flow back to the two lead banks, Maybank and RHB, which are also joint principal advisers.
It also shows both main selling shareholders had borrowed against their stakes. Creador’s vehicle has about RM533 million left before sale expenses after repaying Maybank. Some of the bank facilities were granted on condition that the banks advise on the IPO and are repaid from it. This is disclosed and not unusual in Malaysian IPOs, which is why AmInvestment Bank was appointed as an independent joint principal adviser, but it means the IPO’s arrangers are also among its biggest beneficiaries.
As of 31 August 2026, Big Caring’s indebtedness was RM1.71 billion. After the IPO and repayments, the prospectus puts it at RM1.14 billion.
The business and the numbers
Retail pharmacies made up 92.9% of FY2026 revenue, including e-commerce and corporate sales. The rest came from Medispec, a pharmaceutical distributor bought for RM249.4 million, and Yanling, a supplement manufacturer. The group also owns 57.1% of Your Physio, a physiotherapy chain, and has agreed to buy Singapore’s Yeap Medical Supplies.
| RM million, FYE 30 June | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Revenue | 1,110.7 | 2,171.4 | 3,412.0 | 4,024.0 |
| Gross margin | 20.9% | 21.4% | 24.8% | 30.1% |
| Total income margin* | 26.4% | 26.4% | 28.8% | 33.7% |
| EBITDA | 106.5 | 194.6 | 380.7 | 552.4 |
| Finance costs | 11.6 | 40.2 | 66.3 | 88.5 |
| Profit after tax | 41.2 | 47.8 | 143.0 | 231.8 |
| Profit to shareholders (PATAMI) | 37.0 | 37.2 | 122.3 | 191.6 |
| Operating cash flow | 36.0 | 140.4 | 350.9 | 338.4 |
| Outlets at year end | 267 | 538 | 593 | 646 |
The gross margin jump in FY 2026 is partly accounting. From 1 July 2025, Big Caring started booking product rebates from suppliers as a reduction in the cost of goods, instead of as other income. In FY2025, those rebates were RM32.3 million of other income. So FY2026’s gross margin is not comparable with earlier years. The like-for-like measure, total income margin, still rose from 28.8% to 33.7%, which is an improvement.
| Same-store sales growth | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| BIG outlets | 7.5% | 8.8% | 9.9% |
| CARiNG outlets | 4.5% | 10.3% | 4.9% |
| All outlets | 7.3% | 9.6% | 7.3% |
On the SSSG, BIG is accelerating while CARiNG halved. Store openings are steady, 69, 39, 57 and 58 a year from FY2023 to FY2026. 24 outlets closed in FY2024 after CARiNG was merged in.
While Big Caring does generate good cashflow, its acquisitions ran ahead of it. OCF was RM338.4 million in FY2026, and over four years, the business generated RM865.7 million from operations, spent a whopping RM1.48 billion on investing, mostly on acquisitions and raised RM915 million from financing.
The acquisitions also brought goodwill of RM621.7 million at June 2026, more than the RM456.1 million of equity belonging to shareholders. Pro forma net assets after the IPO are RM0.16 a share, so the IPO price is about 6.8 times book value.
Valuation
At RM1.08 a share, the implied market value of Big Caring is about RM8.0 billion.
| Earnings basis | Profit to shareholders | P/E |
|---|---|---|
| FY2026 reported | RM191.6m | 41.5x |
| FY2026 normalised (interest saved, IPO costs removed) | ~RM223m | ~36x |
| FY2027 illustrative (+15% on normalised) | ~RM256m | ~31x |
The FY2026 normalised P/E is ~36x, and illustrative FY2027 earnings indicate a forward P/E of ~31x.
The company targets a dividend payout of up to 50% of profit attributable to shareholders. If the full 50% is applied to the FY2026 earnings, the dividend yield is about 1.2%.
Big Caring’s valuation is rich and priced at the upside. The case for it is a premium for growth. While FY2026 profit attributable to shareholders rose 56.7%, faster than any peer, much of that came from scale gains on a larger acquired base and a margin uplift that is partly an accounting change. Organic same-store growth of 7% to 10% is closer to 99 Speed Mart’s than the headline suggests.
It is safe to say that the valuations are on generous multiples, and there needs to be momentum on the growth moving forward to justify the implied valuations.
My View
Big Caring may be for investors who are in for the long term, and are onboarded on the defensive play and potential years of consolidation ahead. The IPO price that investors are paying today suits the sellers and the lenders.
The book is now closed. Institutions took their full allocation, cornerstones hold 41% of it, and retail came in 4.31 times oversubscribed. That should support the debut on 19 November, though the stabilisation manager’s over-allotment option and a fully priced offer leave less room for a big first-day pop. For long-term holders, the price only works if profit after normalisation compounds at 15% or more for several years. That requires CARiNG’s same-store growth to recover and new stores to keep paying back. If growth settles near the 7% to 9% target, there is limited upside from RM1.08, and the end of Creador’s lock-up in May 2027 may offer a better entry.
I would argue there are plenty of more straightforward buys since the overall market is jittery now, so I’ll pass on my end.
Join our Telegram to stay updated on the latest investing news: https://t.me/+TXFmvRr6tkgwYTc9




